Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$0.81
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.81
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.49 - $2.25
Previous Close$0.56
Volume32.62K
Average Volume (3M)81.47K
Market Cap
$93.91M
Enterprise Value$63.79
Total Cash (Recent Filing)$16.56M
Total Debt (Recent Filing)$10.21M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Dec 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding92,981,200
10 Day Avg. Volume133,370
30 Day Avg. Volume81,471
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside393.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.1
Revenue Forecast (FY)$95.16M
Bulls Say, Bears Say
Bulls Say
LYMPHIR Commercial AdoptionLYMPHIR is showing measurable early commercial traction in an underserved CTCL segment, with broader institutional access and rising wholesale orders. Continued formulary additions, payer coverage, and reorders could create a durable path toward revenue growth as the launch expands.
Low Financial LeverageVery low leverage reduces interest burden and preserves greater financial flexibility than a heavily indebted development-stage peer. Although the company remains dependent on funding, limited debt may leave more strategic room to support commercialization and manage future capital needs.
Independent GovernanceMaintaining a majority-independent board and adding governance, legal, and regulatory experience can strengthen oversight as CTOR scales LYMPHIR operations. More robust fiduciary and strategic supervision may support disciplined capital allocation and execution over the commercialization period.
Bears Say
No Current Revenue BaseCTOR remains dependent on successful commercialization rather than an established revenue engine. With no reported revenue across the annual periods, operating performance is highly exposed to the pace of LYMPHIR adoption and the company’s ability to convert market access into sustained sales.
Widening Operating LossesLosses have widened substantially while the company has not yet established revenue, indicating that spending is rising ahead of commercial returns. Persistent deterioration in EBIT and net income could prolong the path to profitability and increase reliance on external financing.
Increasing Cash BurnThe worsening cash-flow profile indicates that CTOR is consuming more cash as it advances toward commercialization. Unless LYMPHIR produces a meaningful revenue inflection, continued burn may require additional financing, potentially constraining strategic flexibility and increasing dilution risk.
Citius Oncology News
CTOR FAQ
What was Citius Oncology’s price range in the past 12 months?
Citius Oncology lowest stock price was $0.49 and its highest was $2.25 in the past 12 months.
What is Citius Oncology’s market cap?
Citius Oncology’s market cap is $93.91M.
When is Citius Oncology’s upcoming earnings report date?
Citius Oncology’s upcoming earnings report date is Dec 17, 2026 which is in 75 days.
How were Citius Oncology’s earnings last quarter?
Citius Oncology released its earnings results on Aug 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.01.
Is Citius Oncology overvalued?
According to Wall Street analysts Citius Oncology’s price is currently Undervalued.
Does Citius Oncology pay dividends?
Citius Oncology does not currently pay dividends.
What is Citius Oncology’s EPS estimate?
Citius Oncology’s EPS estimate is -0.19.
How many shares outstanding does Citius Oncology have?
Citius Oncology has 92,981,200 shares outstanding.
What happened to Citius Oncology’s price movement after its last earnings report?
Citius Oncology reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -18.592%.
Which hedge fund is a major shareholder of Citius Oncology?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (393.83% Upside)
$4.00 (393.83% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Citius Oncology
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(393.83% Upside)
Technical Analysis
Ownership Overview
― Insiders
0.79% Mutual Funds
9.36% Other Institutional Investors
89.26% Public Companies and
Individual Investors